Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data

Movement Disorders

Volumn 28, Issue 6, 2013, Pages 705-712

  Proukakis, Christos ^a   Houlden, Henry ^a   Schapira, Anthony H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha synuclein; Etiology of Parkinson's disease; Mosaicism; SNCA; Somatic mutation

Indexed keywords

ALPHA SYNUCLEIN; DNA; GENOMIC DNA;

ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE INSERTION; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTRON; LYMPHOCYTE; MISSENSE MUTATION; MOLECULAR CLONING; MOLECULAR PATHOLOGY; MOSAICISM; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ALPHA-SYNUCLEIN; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PARKINSON DISEASE;

EID: 84879603430     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25502     Document Type: Article

References (83)

1. Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet. 2010;19:R21-R27.
2. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015-1025.
3. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-108.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-2047.
5. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164-173.
6. Proukakis C BT, Mackay D, Houlden H, Schapira AH. A novel alpha-synuclein missense mutation in Parkinson's disease. Neurology. 2013;80:1062-1064.
7. Ibanez P, Lesage S, Janin S, et al. α-Synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009;66:102-108.
8. Mutez E, Leprêtre F, Le Rhun E, et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum Mutat. 2011;32:E2079-E2090.
9. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641-649.
10. Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1, 900 patients. Mov Disord. 2005;20:1191-1194.
11. Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet. 2002;3:748-758.
12. Frank SA. Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010;107(Suppl 1):1725-1730.
13. Rohlin A, Wernersson J, Engwall Y, Wiklund L, Bjork J, Nordling M. Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. Hum Mutat. 2009;30:1012-1020.
14. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96:9236-9241.
15. Vossen RH, Aten E, Roos A, den Dunnen JT. High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat. 2009;30:860-866.
16. Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology. 1998;50:1136-1137.
17. El-Agnaf OM, Curran MD, Wallace A, et al. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases. Neuroreport. 1998;9:3925-3927.
18. Neystat M, Lynch T, Przedborski S, Kholodilov N, Rzhetskaya M, Burke RE. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov Disord. 1999;14:417-422.
19. Pamphlett R. Somatic mutation: a cause of sporadic neurodegenerative diseases? Med Hypotheses. 2004;62:679-682.
20. Van Broeckhoven C. The future of genetic research on neurodegeneration. Nat Med. 2010;16:1215-1217.
21. Schneider SA, Johnson MR. Monozygotic twins with LRRK2 mutations: genetically identical but phenotypically discordant. Mov Disord. 2012;27:1203-1204.
22. Xiromerisiou G, Houlden H, Sailer A, Silveira-Moriyama L, Hardy J, Lees AJ. Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord. 2012;27:1323-1323.
23. Beck JA, Poulter M, Campbell TA, et al. Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum Mol Genet. 2004;13:1219-1224.
24. Depienne C, Fedirko E, Faucheux J-M, et al. A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP. Neurogenetics. 2007;8:231-233.
25. Haack TB, Hogarth P, Kruer MC, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet. 2012;91:1144-1149.
26. Cancel G, Gourfinkel-An I, Stevanin G, et al. Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. Hum Mutat. 1998;11:23-27.
27. Chong SS, McCall AE, Cota J, et al. Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1995;10:344-350.
28. Lokanga RA, Entezam A, Kumari D, et al. Somatic expansion in mouse and human carriers of fragile X premutation alleles. Hum Mutat. 2013;34:157-166.
29. Beck J, Poulter M, Hensman D, et al. Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. Am J Hum Genet. 2013;92:345-353.
30. Montermini L, Kish SJ, Jiralerspong S, Lamarche JB, Pandolfo M. Somatic mosaicism for Friedreich's ataxia GAA triplet repeat expansions in the central nervous system. Neurology. 1997;49:606-610.
31. Swami M, Hendricks AE, Gillis T, et al. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet. 2009;18:3039-3047.
32. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38:515-517.
33. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet. 2006;38:518-520.
34. Lin MT, Cantuti-Castelvetri I, Zheng K, et al. Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol. 2012;71:850-854.
35. Bastien R, Lewis TB, Hawkes JE, et al. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat. 2008;29:757-764.
36. Kehrer-Sawatzki H, Cooper DN. Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J Med Genet. 2008;45:622-631.
37. Vadlamudi L, Dibbens LM, Lawrence KM, et al. Timing of de novo mutagenesis-a twin study of sodium-channel mutations. N Engl J Med. 2010;363:1335-1340.
38. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord. 2013 [Epub ahead of print].
39. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience. 2008;153:733-750.
40. Braak H, Tredici KD, Udo R, Rob AIdV, Ernst NHJS, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
41. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord. 2012;27:8-30.
42. Dickson D, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;115:437-444.
43. Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord. 2009;15:516-520.
44. Enqvist S, Sletten K, Stevens FJ, Hellman U, Westermark P. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS One. 2007;2:e981.
45. Beach T, Adler C, Sue L, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689-702.
46. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol. 2007;66:354-362.
47. Miki Y, Mori F, Wakabayashi K, Kuroda N, Orimo S. Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord. 2009;24:2299-2301.
48. Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. Biochem Soc Trans. 2005;33:578-581.
49. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2009;106:12571-12572.
50. Pamphlett R. The "somatic-spread" hypothesis for sporadic neurodegenerative diseases. Med Hypotheses. 2011;77:544-547.
51. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord. 2012;27:831-842.
52. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord. 2013;28:41-50.
53. Abyzov A, Mariani J, Palejev D, et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature. 2012;492:438-442.
54. Mkrtchyan H, Gross M, Hinreiner S, et al. Early embryonic chromosome instability results in stable mosaic pattern in human tissues. PLoS One. 2010;5:e9591.
55. Piotrowski A, Bruder CE, Andersson R, et al. Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat. 2008;29:1118-1124.
56. Bruder CE, Piotrowski A, Gijsbers AA, et al. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet. 2008;82:763-771.
57. Arlt MF, Wilson TE, Glover TW. Replication stress and mechanisms of CNV formation. Curr Opin Genet Dev. 2012;22:204-210.
58. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011;471:58-62.
59. Rozier L, El-Achkar E, Apiou F, Debatisse M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene. 2004;23:6872-6880.
60. Mitsui J, Takahashi Y, Goto J, et al. Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet. 2010;87:75-89.
61. McKinnon PJ. DNA repair deficiency and neurological disease. Nat Rev Neurosci 2009;10:100-112.
62. Rodriguez-Santiago B, Malats N, Rothman N, et al. Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J Hum Genet. 2010;87:129-138.
63. Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci U S A. 2001;98:13361-13366.
64. Iourov IY, Vorsanova SG, Liehr T, Yurov YB. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol Dis. 2009;34:212-220.
65. Arendt T, Bruckner MK, Mosch B, Losche A. Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol. 2010;177:15-20.
66. Baillie JK, Barnett MW, Upton KR, et al. Somatic retrotransposition alters the genetic landscape of the human brain. Nature. 2011;479:534-537.
67. Coufal NG, Garcia-Perez JL, Peng GE, et al. L1 retrotransposition in human neural progenitor cells. Nature. 2009;460:1127-1131.
68. Gavrilov LA, Gavrilova NS. Early-life programming of aging and longevity: the idea of high initial damage load (the HIDL hypothesis). Ann N Y Acad Sci. 2004;1019:496-501.
69. Khrapko K, Ebralidse K, Kraytsberg Y. Where and when do somatic mtDNA mutations occur? Ann N Y Acad Sci. 2004;1019:240-244.
70. Macosko EZ, McCarroll SA. Exploring the variation within. Nat Genet. 2012;44:614-616.
71. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci. 1991;14:453-501.
72. Oo TF, Burke RE. The time course of developmental cell death in phenotypically defined dopaminergic neurons of the substantia nigra. Brain Res Dev Brain Res. 1997;98:191-196.
73. Dreyer WJ GW, Hood L. The Genetic, Molecular, and Cellular Basis of Antibody Formation: Some Facts and a Unifying Hypothesis. Cold Spring Harb Symp Quant Biol. 1967;32:353-367.
74. Peterson SE, Yang AH, Bushman DM, et al. Aneuploid cells are differentially susceptible to caspase-mediated death during embryonic cerebral cortical development. J Neurosci. 2012;32:16213-16222.
75. Bayer TA, Jakala P, Hartmann T, et al. Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport. 1999;10:2799-2803.
76. Galvin JE, Schuck TM, Lee VMY, Trojanowski JQ. Differential expression and distribution of α-, β-, and γ-synuclein in the developing human substantia nigra. Exp Neurol. 2001;168:347-355.
77. Raghavan R, Kruijff L, Sterrenburg MD, Rogers BB, Hladik CL, White CL 3rd. Alpha-synuclein expression in the developing human brain. Pediatric Develop Pathol. 2004;7:506-516.
78. Singer T, McConnell MJ, Marchetto MC, Coufal NG, Gage FH. LINE-1 retrotransposons: mediators of somatic variation in neuronal genomes? Trends Neurosci. 2010;33:345-354.
79. Milbury CA, Li J, Makrigiorgos GM. COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem. 2009;55:2130-2143.
80. Payne BA, Wilson IJ, Yu-Wai-Man P, et al. Universal heteroplasmy of human mitochondrial DNA. Hum Mol Genet. 2013;22:384-390.
81. Gerstung M, Beisel C, Rechsteiner M, et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun. 2012;3:811.
82. Izawa K, Hijikata A, Tanaka N, et al. Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing. DNA Res. 2012;19:143-152.
83. Valli R, Marletta C, Pressato B, et al. Comparative genomic hybridization on microarray (a-CGH) in constitutional and acquired mosaicism may detect as low as 8% abnormal cells. Molec Cytogenet. 2011;4:13.